Dose escalation will continue, despite satisfaction of the primary endpoint of study (> 50,000 and > 20,000 above baseline), unless the platelet count reaches 100,000. The rationale for this approach is to maximize clinically relevant responses for the subjects and standardize data for analysis. Subjects will stop study medication if the platelet count is within the normal range, thereby minimizing any safety risk associated with elevated platelet count. By continuing to dose escalate subjects until the platelet count is > 100,000, the maximum response and correlation of dose will be tracked allowing better understanding of sustained response and dose-dependent response, which can be applied to future consideration dosage for periods of short-term hemostasis ( i.e surgical procedures). The 8 weeks of data collected in enrolled subjects on the standardized protocol will have the balance of consistency of dosage and unequivocality of response while maintaining subject safety.